$170.31 Million in Sales Expected for Myriad Genetics, Inc. (NASDAQ:MYGN) This Quarter

Wall Street brokerages predict that Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) will announce sales of $170.31 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Myriad Genetics’ earnings. The lowest sales estimate is $164.60 million and the highest is $176.10 million. Myriad Genetics reported sales of $189.40 million […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,United States ,Blackrock , ,Zacks Investment Research ,Wellington Management Group ,Blackrock Inc ,Renaissance Technologies ,Genetics Company Profile Get Rating ,Nasdaq ,Genetics Inc ,Balyasny Asset Management ,Goldman Sachs Group ,Polar Asset Management Partners Inc ,Wall Street ,Myriad Genetics ,Get Rating ,Myriad Genetic ,Management Group ,Asset Management Partners ,Asset Management ,Genetics Company Profile ,Myrisk Hereditary Cancer Test ,Germline Companion Diagnostic Test ,Companion Diagnostic Test ,Nasdaq Mygn ,Mygn ,Medical ,62855j10 ,Ratings ,Consensus ,